
Look beyond the delivery count.
A homecare medicines service connects prescribing, pharmacy, logistics, nursing support where required and communication with the person receiving treatment. A contract can meet a headline measure while staff and patients still spend effort resolving exceptions. Our proposed PHARMORIS evaluation concerns the organisational review of one defined homecare pathway. It asks whether a source-linked account of service responsibilities and unresolved issues can help a trust make a better improvement decision, without claiming to manage an individual's treatment or replace the contracted provider's systems.
In development · Intended scope and questions for evaluation
The organisation.
The people around it.
A monitoring plan needs an agreed requesting role, reviewing role and escalation route. A document being sent does not establish that the receiving team has accepted the work.
The people involved
Care homes, domiciliary care, community providers, specialist homecare services and their clinical and operational partners.
The dependencies
Residents and carers, care-home staff, community nursing, GPs, specialist prescribers, pharmacy and homecare providers.
What to examine
Accepted responsibilities, communications, monitoring and escalation, staff time, service continuity and the burden on people receiving care.
An illustrative set of programme relationships. The actual participants, authority, funding and permissions must be established for the defined setting. Explore every organisation perspective.
Match the review to the actual service.
NHS England publishes homecare context within its medicines procurement resources, including national performance measures (NHS England, n.d.). The local review still needs to establish the service scope and contractual responsibilities. A low-complexity delivery arrangement and a service with clinical support should not be assessed as though they involve identical work. Identify which organisations provide each element, the agreed exception routes and the measures that apply. That prevents an appealing comparison from concealing important differences in what patients and clinical teams need.
Follow an exception across organisations.
The difficult part may begin when a prescription, delivery or supporting information does not arrive as expected. A useful process review asks who detects the problem, who can resolve it and how the person is kept informed. Include the effort required from the trust and the provider, rather than counting only the final outcome. Avoid assuming that a completed delivery means the entire episode was straightforward. The proposed analysis would seek a clearer account of coordination, with sensitive details kept within authorised arrangements.
Separate contract performance from patient experience.
A dashboard measure and a person's experience answer different questions. Both may matter, but one should not be used as a proxy for the other without evidence. Define the reporting period, denominator and exclusions for each service measure. Record whether an exception is still open and how repeat contacts are counted. A well-designed review makes limitations visible and gives service owners questions they can act on. It should not manufacture a single satisfaction or quality score from incompatible sources.
For an operational measure, specify the event and denominator together. Delivery exceptions per scheduled delivery describe something different from people experiencing at least one exception during a period. Repeated problems affecting one person should not disappear inside a favourable average. Keep outstanding and resolved episodes distinct, with a consistent reporting window. These choices can make a review more useful before any new software is introduced, and provide a fairer basis for evaluating preparation support.
Compare the review pack with normal practice.
An initial PHARMORIS evaluation could use approved service documents, permitted aggregate performance information and synthetic exception scenarios. Compare preparation of a pathway brief with the trust's existing service-review method. Reviewers from pharmacy, homecare operations and contract management would identify the essential responsibilities and unresolved questions. The first task would not alter deliveries, contact patients or interpret treatment information. It would test whether the support improves the quality and total effort of organisational review before any operational integration is considered.
Measure whether the next action becomes clearer.
Candidate outcomes include contradictions identified, missing responsibilities, traceability of performance claims and time required to prepare and correct the brief. A later governed evaluation might examine chasing effort or the resolution of defined administrative exceptions. Financial value would need observed inputs and a clear account of who benefits. Do not describe fewer messages as better service if people have simply lost a route to raise a concern. The comparison should preserve the person receiving care as an important perspective, not an invisible endpoint.
Stop if the brief hides a service gap.
Stop if a draft merges unlike services, presents an unresolved issue as closed or attributes responsibility without evidence from the actual arrangement. Reassess if the checking burden exceeds the usefulness of the output. If the main problem is contractual ambiguity, the next step may be a governance or contract discussion rather than software development. That is a credible finding. A commercially valuable tool should help teams see where its role ends and where a decision from accountable organisations is required.
Bring one pathway and one decision.
A trust homecare pharmacist, service manager and contract owner can begin with the next review they need to prepare. We can discuss the scope, permitted sources and the comparison that would show whether PHARMORIS adds value. The proposition is a focused organisational evaluation, not a claim that NEUVIOR delivers homecare services or has integrated with a provider. A useful pilot would earn its next step through clear findings about quality, effort and the decisions the brief helps the team make.
Sources and further reading
NHS England (n.d.) Medicines procurement and supply chain. Available at: https://www.england.nhs.uk/medicines-2/medicines-value-and-access/medicines-procurement-and-supply-chain/ (Accessed: 14 October 2026).
Bring the question
your organisation
needs to move.
Tell us where the programme gets stuck, who is affected and what a worthwhile evaluation would help you decide.
Discuss a PHARMORIS evaluationAn initial conversation should describe the organisational question. Agree the purpose and information requirements before sharing records.